Women's Cancer Program

妇女癌症计划项目摘要 女性癌症计划(WCP)是一个高度互动的多学科研究计划，由Dr。 Goetz、Degnim和Bakkum-Gamez，由61名基础和人口科学家和临床人员组成 来自明尼苏达州罗切斯特、亚利桑那州和佛罗里达州梅奥诊所14个部门和中心的调查人员。它的 总体目标是促进对乳房和妇科的了解和管理策略。 癌症。大量的计划内互动反映了多学科的WCP团队专注于4 主要的具体目标：1)基因组学：确定宿主和肿瘤的遗传改变；2)生物学：确定 女性癌症生物学中的关键介质和途径；3)风险评估的进展：确定 风险增加的妇女亚群；以及4)新的临床策略：开发和测试创新的临床 战略，特别是基于对具体目标1-3的发现。WCP坚实的科学基础和 互动的机会导致了梅奥诊所乳腺和卵巢孢子的更新和 在当前项目期间，新的抗击癌症、国防部和多个R01赠款。所有这些助学金 在梅奥诊所和包括联盟在内的临床试验网络内支持研究人员发起的临床试验 临床试验、转化型乳腺癌研究联盟和抗癌组织 协作，得到计划成员的广泛参与。直接同行评审的赠款资金总额 该计划的费用为530万美元，其中56%来自NCI。该计划还有1440万美元的直接、非同行审查 资金问题。自2013年以来，计划成员为文献贡献了978种出版物；49%代表 方案内工作，29%反映方案间协作，158(16%)在期刊上有 影响因子≥10。其中一些工作改变了临床实践，包括对BRCA2变体的重新分类 未知的意义；开发和实施新的乳腺癌风险模型；共同开发 Rucaparib的应用，导致FDA批准PARP抑制剂并将其扩展到高级别浆液性卵巢 生殖系BRCA1或BRCA2突变的癌症与临床药物遗传学的发展 实施联盟(CPIC)关于使用CYP2D6基因来指导 他莫昔芬治疗。WCP成员受益于大量共享资源的使用，尤其是 生物菌种的加入和加工、病理学研究、生物统计学、调查研究和 MCCC临床研究办公室。为了促进新的合作并保持持续的合作，该计划 每月科学研讨会和乳癌和妇科癌症小组会议，每周一次 乳腺癌和妇科癌症研究人员的多学科会议，每季度联合乳腺癌和妇科 妇科癌症会议，以及年度多学科乳腺继续医学教育课程，在三个 蛋黄酱网站。女性癌症相关研究得到了机构和癌症中心的大力支持， 教育、外展和临床实践的努力。

WOMEN'S CANCER PROGRAM PROJECT SUMMARY The Women's Cancer Program (WCP) is a highly interactive, multidisciplinary research program co-led by Drs. Goetz, Degnim, and Bakkum-Gamez and composed of 61 basic and population scientists and clinical investigators from 14 departments and centers at Mayo Clinic in Rochester, MN; Arizona; and Florida. Its overarching goal is to advance the understanding of, and management strategies for, breast and gynecologic cancers. The substantial intraprogrammatic interactions reflect multidisciplinary WCP teams that focus on 4 major Specific Aims: 1) Genomics: to determine both host and tumor genetic alterations; 2) Biology: to define key mediators and pathways in the biology of women's cancers; 3) Advances in risk assessment: to define subgroups of women at increased risk; and 4) New clinical strategies: to develop and test innovative clinical strategies, especially based on discoveries from Specific Aims 1-3. The WCP's solid scientific base and opportunities for interactions have resulted in the renewal of the Mayo Clinic Breast and Ovarian SPOREs and new Stand Up to Cancer, DoD, and multiple R01 grants during the current project period. All of these grants support investigator-initiated clinical trials at Mayo Clinic and within clinical trial networks, including the Alliance for Clinical Trials, the Translational Breast Cancer Research Consortium, and the Stand Up to Cancer collaboration, with broad participation by Program members. Total direct peer-reviewed grant funding within the Program is $5.3M, with 56% from NCI. The Program has an additional $14.4M in direct, non-peer-reviewed funding. Since 2013, Program members have contributed 978 publications to the literature; 49% represent intraprogrammatic work, 29% reflect interprogrammatic collaborations, and 158 (16%) are in journals with an impact factor ≥10. Some of this work has changed clinical practice, including reclassification of BRCA2 variants of unknown significance; development and implementation of a new breast cancer risk model; co-development of rucaparib, resulting in FDA approval and extension of PARP inhibitors beyond high-grade serous ovarian cancers with germline BRCA1 or BRCA2 mutations; and the development of Clinical Pharmacogenetics Implementation Consortium (CPIC) practice guidelines regarding the use of CYP2D6 genotype to guide tamoxifen treatment. WCP members benefit from the use of numerous Shared Resources, especially Biospecimens Accessioning and Processing, Pathology Research, Biostatistics, Survey Research, and the MCCC Clinical Research Office. To catalyze new and maintain ongoing collaborations, the Program has monthly scientific symposia and Breast and Gynecologic Cancer Disease Group meetings, weekly multidisciplinary conferences for breast and gynecologic cancer researchers, quarterly combined breast and gynecologic cancer conferences, and yearly multidisciplinary breast CME courses that rotate among the 3 Mayo sites. There is significant institutional and Cancer Center support for women's cancer–related research, education, outreach, and clinical practice endeavors.